Literature DB >> 15377470

Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.

Giorgio Malpeli1, Stefano Barbi, Patrick S Moore, Maria Scardoni, Marco Chilosi, Aldo Scarpa, Fabio Menestrina.   

Abstract

BACKGROUND AND OBJECTIVES: Somatic hypermutation of the BCL6 gene and its expression in lymphoma represent specific markers for B-cell transit through the germinal center. Thus, analysis of BCL6 may aid in clarifying the relationship between primary mediastinal B-cell lymphoma (PMBL) and other non-thymic diffuse large cell lymphomas (DLCL). DESIGN AND METHODS: Twenty-four PMBL were analyzed for BCL6 status, including first intron mutations, by quantitative reverse transcription polymerase chain reaction (RT-PCR), and immunohistochemistry. We also performed a meta-analysis of reported BCL6 mutations in PMBL (n=141), DLCL (n=233), and follicular lymphoma (n=120).
RESULTS: Thirteen PMBL (54%) showed hypermutation of BCL6. All cases showed bcl6 mRNA and immunohistochemical expression. Meta-analysis demonstrated that the preferentially altered sequence motifs of BCL6 in PMBL were TA (p=0.002) and AT (p=0.0008) dinucleotides and TAT trinucleotides (p=0.001). GC and RGYW/WRCY motifs were a target in DLCL and FL but not in PMBL. Moreover, the DNA stretch spanning nucleotides 150-270 was highly targeted only in PMBL. INTERPRETATION AND
CONCLUSIONS: The consistent expression of bcl6 protein and occurrence of hypermutation indicate that PMBL should be considered of germinal center origin. The fact that the hypermutation sites and mutational spectrum of BCL6 in PMBL differ from those found in FL and DLCL might suggest that the maturation block of the transforming cells differs among these tumor types, and that the characteristic mutational pattern is present before neoplastic transformation. Thus, our findings strengthen the hypothesis that PMBL originate from an already defined sub-population of B-cells, which are different from those leading to either DLCL or FL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15377470

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  8 in total

1.  Ancient phylogenetic beginnings of immunoglobulin hypermutation.

Authors:  Jaroslav Kubrycht; Karel Sigler; Michal Růzicka; Pavel Soucek; Jirí Borecký; Petr Jezek
Journal:  J Mol Evol       Date:  2006-10-06       Impact factor: 2.395

2.  Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.

Authors:  J Iqbal; T C Greiner; K Patel; B J Dave; L Smith; J Ji; G Wright; W G Sanger; D L Pickering; S Jain; D E Horsman; Y Shen; K Fu; D D Weisenburger; C P Hans; E Campo; R D Gascoyne; A Rosenwald; E S Jaffe; J Delabie; L Rimsza; G Ott; H K Müller-Hermelink; J M Connors; J M Vose; T McKeithan; L M Staudt; W C Chan
Journal:  Leukemia       Date:  2007-07-12       Impact factor: 11.528

3.  A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression.

Authors:  Ai Kotani; Il-Mi Okazaki; Masamichi Muramatsu; Kazuo Kinoshita; Nasim A Begum; Toshiharu Nakajima; Hirohisa Saito; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-14       Impact factor: 11.205

4.  Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.

Authors:  Olga Ritz; Chrystelle Guiter; Flavia Castellano; Karola Dorsch; Julia Melzner; Jean-Philippe Jais; Gwendoline Dubois; Philippe Gaulard; Peter Möller; Karen Leroy
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

5.  Identification of murine B cell lines that undergo somatic hypermutation focused to A:T and G:C residues.

Authors:  Palash Bhattacharya; Fernando Grigera; Igor B Rogozin; Thomas McCarty; Herbert C Morse; Amy L Kenter
Journal:  Eur J Immunol       Date:  2008-01       Impact factor: 5.532

6.  STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL).

Authors:  Olga Ritz; Karolin Rommel; Karola Dorsch; Elena Kelsch; Julia Melzner; Michaela Buck; Karen Leroy; Vasiliki Papadopoulou; Simon Wagner; Ralf Marienfeld; Silke Brüderlein; Jochen K Lennerz; Peter Möller
Journal:  Oncotarget       Date:  2013-07

7.  Knock-down of BCL6 / STAT6 sensitizes primary B cell lymphoma cells for treatment with current therapeutic agents.

Authors:  Marie-Therese Häberle; Elena Kelsch; Karola Dorsch; Peter Möller; Olga Ritz
Journal:  Oncoscience       Date:  2014-04-30

8.  Primary mediastinal large B-cell lymphoma.

Authors:  Anna Dabrowska-Iwanicka; Jan A Walewski
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.